This study looks at how well two medicines, **Cabotegravir Ultra Long-Acting (CAB ULA)** and **Rilpivirine Ultra Long-Acting (RPV ULA)**, work for people with HIV. HIV is a virus that attacks the immune system. The study includes people aged 12 and older who have been taking regular HIV medicines and have very low virus levels in their blood. The study will check if these medicines are safe and if people can tolerate them well. **Virologically suppressed** means the virus is under control with current treatment. People who join must have been on their current HIV pills for at least 6 months without stopping. They cannot join if they have certain health problems or have tried similar long-acting treatments before. **Key Points:** - Participants must visit the study site regularly for check-ups. - The study involves using long-acting shots, so fewer daily pills. - No prior use of similar treatments is allowed. If you qualify and are interested, this study could mean fewer HIV pills with regular check-ups to ensure safety and effectiveness.

Remember to discuss any study with your doctor to see if it is right for you!